Response to Amgen’s KRAS inhibitor declines as more patients added in NSCLC cohort

The partial response rate reported Sunday from the high dose of Amgen’s KRAS inhibitor AMG 510 had nowhere to go but down, given that the 100% PR rate seen earlier this year was from just three patients. While the metric fell farther than investors expected, the company said it may seek approval based an ongoing Phase II study, which is using the dose.

Among 13 evaluable patients treated with the 960 mg high dose in the Phase I trial to treat KRAS G12C mutant advanced stage NSCLC, 54% (7/13) had a partial response. The remaining six patients had stable disease (46%) for a disease control rate of 100%. ...